ABCL News and Press, AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) will announce its second quarter 2024 financial results on Tuesday, August 6, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link t...

2024-06-13 05:40:00 ET Discovering new drugs can be a lucrative endeavor, but things aren't working out lately for AbCellera Biologics (NASDAQ: ABCL) . Shares of this unusual biotech stock are down by about 57% from the high water mark they set last summer. The steep losses migh...

2024-06-11 00:24:03 ET Summary Baker Brothers' 13F portfolio value decreased from $8.79B to $7.97B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. Baker Brothers has had successful investments in companies that ...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024, at 12:20 p.m. Pacific Time (3:20 p.m. Eastern Time). A live audio webcast of the presentation may be accessed throug...

2024-05-16 08:39:00 ET Summary AbCellera's valuation has shrunk by 80% since its IPO due to the withdrawal of its COVID antiviral, bamlanivimab. The company reported Q1 2024 revenues of $10 million, down from $12.2 million in the prior year period. AbCellera is focusing on com...

2024-05-15 23:17:57 ET Summary AbCellera Biologics is a drug discovery company focused on developing antibody therapies. While the company has developed a technology platform that is open to customers, the current market environment has accelerated its shift towards advancing inte...

2024-05-08 17:30:13 ET KeyBanc analyst issues OVERWEIGHT recommendation for ABCL on May 8, 2024 02:46AM ET. The previous analyst recommendation was Overweight. ABCL was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

2024-05-08 04:30:12 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q1 2024 Earnings Call May 07, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q1 2024 Earnings Call Tran...

2024-05-07 23:00:08 ET AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Conference Call May 07, 2024 05:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Executive Officer Andrew Booth - Chief Financi...

2024-05-07 16:31:09 ET More on AbCellera Biologics AbCellera: Victim Of Its Own Success AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript AbCellera Biologics: Continuing To Expand Partnerships AbCellera partners with PE firms to develop antibod...